|
|
|
|
|
|
|
|
|
|
"To date, several investigators (Table 1) have explored bevacizumab as a single agent or in combination with metronomic chemotherapy in the management of advanced ovarian cancer. All studies to date with bevacizumab as a single agent or in combination with chemotherapy have shown promising responses...."
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.